La Jolla Pharmaceutical Company Company Profile (NASDAQ:LJPC)

About La Jolla Pharmaceutical Company (NASDAQ:LJPC)

La Jolla Pharmaceutical Company logoLa Jolla Pharmaceutical Company is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies to improve outcomes in patients suffering from life-threatening diseases. LJPC-501 is its formulation of angiotensin II for the potential treatment of catecholamine-resistant hypotension (CRH). It has initiated a Phase III trial of LJPC-501 for the treatment of CRH, called the Angiotensin II for the Treatment of High-Output Shock 3 (ATHOS) Phase III trial. LJPC-401 is its formulation of synthetic human hepcidin for the potential treatment of conditions characterized by iron overload, such as hereditary hemochromatosis, beta thalassemia, sickle cell disease and myelodysplastic syndrome. LJPC-30S is its next-generation gentamicin derivative program that is focused on therapeutics for the potential treatment of serious bacterial infections, as well as rare genetic disorders, such as cystic fibrosis and Duchenne muscular dystrophy.

Industry, Sector and Symbol: Capitalization:
  • Market Cap: $750.63 million
  • Outstanding Shares: 22,123,000
Average Prices:
  • 50 Day Moving Avg: $34.15
  • 200 Day Moving Avg: $30.90
  • 52 Week Range: $14.63 - $39.28
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -8.55
  • P/E Growth: -0.53
Sales & Book Value:
  • Annual Revenue: $128,999.00
  • Price / Sales: 5,818.91
  • Book Value: $6.04 per share
  • Price / Book: 5.62
Profitability:
  • EBITDA: ($95,320,000.00)
  • Return on Equity: -91.66%
  • Return on Assets: -80.61%
Debt:
  • Current Ratio: 17.41%
  • Quick Ratio: 17.41%
Misc:
  • Average Volume: 270,814 shs.
  • Beta: 1.74
  • Short Ratio: 23.18
 

Frequently Asked Questions for La Jolla Pharmaceutical Company (NASDAQ:LJPC)

What is La Jolla Pharmaceutical Company's stock symbol?

La Jolla Pharmaceutical Company trades on the NASDAQ under the ticker symbol "LJPC."

How were La Jolla Pharmaceutical Company's earnings last quarter?

La Jolla Pharmaceutical Company (NASDAQ:LJPC) issued its quarterly earnings data on Thursday, July, 27th. The company reported ($1.21) earnings per share for the quarter, missing the Zacks' consensus estimate of ($1.13) by $0.09. During the same period in the previous year, the company posted ($0.90) earnings per share. View La Jolla Pharmaceutical Company's Earnings History.

When will La Jolla Pharmaceutical Company make its next earnings announcement?

La Jolla Pharmaceutical Company is scheduled to release their next quarterly earnings announcement on Thursday, November, 2nd 2017. View Earnings Estimates for La Jolla Pharmaceutical Company.

Where is La Jolla Pharmaceutical Company's stock going? Where will La Jolla Pharmaceutical Company's stock price be in 2017?

6 analysts have issued 12 month target prices for La Jolla Pharmaceutical Company's shares. Their forecasts range from $36.00 to $85.00. On average, they anticipate La Jolla Pharmaceutical Company's share price to reach $54.60 in the next year. View Analyst Ratings for La Jolla Pharmaceutical Company.

What are analysts saying about La Jolla Pharmaceutical Company stock?

Here are some recent quotes from research analysts about La Jolla Pharmaceutical Company stock:

  • 1. According to Zacks Investment Research, "LA JOLLA PHARMACEUTICAL CO. is engaged in the research and development of therapeutic products for the treatment of autoimmune and inflammatory diseases. " (10/17/2017)
  • 2. Cowen and Company analysts commented, "LJPC reported Q1 financials." (4/28/2017)
  • 3. Chardan Capital analysts commented, "We believe the results are compelling and, based on the SPA, will likely result in LJPC-501 US approval. Recall from our 24 January 2017 note where we discussed the SPA, stating with regards to the primary endpoint," (3/2/2017)
  • 4. SunTrust Banks, Inc. analysts commented, "strong" ATHOS-3 data which implies LJPC-501 could be standard-of-care in last-line CRH.Suneja commented, "We believe today's highly favorable ATHOS-3 data (primary endpoint met; positive trend in mortality) are supportive of approval in CRH, which could be at least $500MM opportunity; an NDA filing is expected in 2H17 and full data are expected in 2017 at a major medical conference and publication in a "top-tier" journal. In our view, these results provide validation for LJPC's capital-efficient strategy of developing naturally occurring peptides with well-understood biological functions for life-threatening diseases. We reiterate our Buy rating and increase our NPV-derived PT to $57 from $38." (2/27/2017)

Who are some of La Jolla Pharmaceutical Company's key competitors?

Who are La Jolla Pharmaceutical Company's key executives?

La Jolla Pharmaceutical Company's management team includes the folowing people:

  • Kevin C. Tang, Chairman of the Board
  • George F. Tidmarsh M.D. Ph.D., President, Chief Executive Officer, Secretary, Director
  • Dennis M. Mulroy CPA, Chief Financial Officer
  • Jennifer A. Carver, Senior Vice President,Operations
  • Lakhmir S. Chawla M.D., Chief Medical Officer
  • Laura Douglass, Independent Director
  • Craig A. Johnson, Independent Director
  • Robert Harvey Rosen, Independent Director

How do I buy La Jolla Pharmaceutical Company stock?

Shares of La Jolla Pharmaceutical Company can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is La Jolla Pharmaceutical Company's stock price today?

One share of La Jolla Pharmaceutical Company stock can currently be purchased for approximately $33.93.


MarketBeat Community Rating for La Jolla Pharmaceutical Company (NASDAQ LJPC)
Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  165 (Vote Outperform)
Underperform Votes:  94 (Vote Underperform)
Total Votes:  259
MarketBeat's community ratings are surveys of what our community members think about La Jolla Pharmaceutical Company and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for La Jolla Pharmaceutical Company (NASDAQ:LJPC) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 6 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $54.60 (60.92% upside)
Consensus Price Target History for La Jolla Pharmaceutical Company (NASDAQ:LJPC)
Price Target History for La Jolla Pharmaceutical Company (NASDAQ:LJPC)
Analysts' Ratings History for La Jolla Pharmaceutical Company (NASDAQ:LJPC)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/3/2017Jefferies Group LLCReiterated RatingBuy$40.00LowView Rating Details
8/30/2017J P Morgan Chase & CoInitiated CoverageOverweight -> Overweight$36.00LowView Rating Details
8/8/2017Chardan CapitalReiterated RatingBuy$85.00LowView Rating Details
5/22/2017SunTrust Banks, Inc.Reiterated RatingBuy$57.00MediumView Rating Details
4/30/2017Noble FinancialReiterated RatingBuyLowView Rating Details
4/28/2017Cowen and CompanyReiterated RatingBuy$55.00LowView Rating Details
5/24/2016Lake Street CapitalInitiated CoverageBuy$25.00N/AView Rating Details
(Data available from 10/23/2015 forward)

Earnings

Earnings History for La Jolla Pharmaceutical Company (NASDAQ:LJPC)
Earnings by Quarter for La Jolla Pharmaceutical Company (NASDAQ:LJPC)
Earnings History by Quarter for La Jolla Pharmaceutical Company (NASDAQ LJPC)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/2/2017        
7/27/2017Q2 2017($1.13)($1.21)$0.03 millionViewN/AView Earnings Details
4/27/2017Q1 2017($1.34)($1.26)$0.17 millionViewN/AView Earnings Details
2/23/2017Q4 2016($1.20)($1.44)$0.16 million$0.09 millionViewN/AView Earnings Details
11/3/2016Q3($0.97)($1.23)$0.26 million$0.04 millionViewN/AView Earnings Details
8/8/2016Q2($0.99)($0.90)$0.25 million$0.25 millionViewN/AView Earnings Details
5/6/2016Q416($0.74)($0.96)$0.43 million$0.23 millionViewN/AView Earnings Details
2/25/2016Q4($0.72)($0.69)$0.41 millionViewN/AView Earnings Details
11/6/2015Q315($0.69)($0.70)$0.65 millionViewN/AView Earnings Details
8/7/2015Q215($0.61)($0.70)ViewN/AView Earnings Details
3/16/2015Q414($0.37)($0.45)ViewN/AView Earnings Details
11/12/2014Q314($0.42)($0.37)ViewN/AView Earnings Details
8/14/2014Q214($0.69)($0.63)ViewN/AView Earnings Details
4/30/2014Q1 2014($0.91)($0.93)ViewN/AView Earnings Details
3/31/2014($0.24)($0.07)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for La Jolla Pharmaceutical Company (NASDAQ:LJPC)
2017 EPS Consensus Estimate: ($4.89)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($1.39)($1.25)($1.32)
Q2 20172($1.26)($1.01)($1.14)
Q3 20172($1.26)($1.10)($1.18)
Q4 20172($1.31)($1.19)($1.25)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for La Jolla Pharmaceutical Company (NASDAQ:LJPC)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for La Jolla Pharmaceutical Company (NASDAQ:LJPC)
Insider Ownership Percentage: 25.47%
Insider Trades by Quarter for La Jolla Pharmaceutical Company (NASDAQ:LJPC)
Institutional Ownership by Quarter for La Jolla Pharmaceutical Company (NASDAQ:LJPC)
Insider Trades by Quarter for La Jolla Pharmaceutical Company (NASDAQ:LJPC)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
3/23/2017Kevin C TangDirectorBuy149,254$33.50$5,000,009.00View SEC Filing  
3/3/2017Dennis MulroyCFOBuy500$33.95$16,975.00View SEC Filing  
3/3/2017George F TidmarshCEOBuy3,000$34.17$102,510.00View SEC Filing  
3/3/2017Lakhmir S ChawlaInsiderBuy1,600$34.80$55,680.00View SEC Filing  
9/13/2016Kevin C TangDirectorBuy139,035$19.82$2,755,673.70View SEC Filing  
3/4/2016Kevin C TangDirectorBuy20,000$19.85$397,000.00View SEC Filing  
3/1/2016George F TidmarshCEOBuy2,000$16.57$33,140.00View SEC Filing  
9/28/2015Lakhmir S ChawlaInsiderBuy485$27.75$13,458.75View SEC Filing  
9/10/2015Kevin C TangDirectorBuy80,000$38.00$3,040,000.00View SEC Filing  
8/21/2015Kevin C TangDirectorBuy170,000$27.11$4,608,700.00View SEC Filing  
6/26/2015Kevin C TangDirectorBuy110,000$23.58$2,593,800.00View SEC Filing  
6/24/2015Kevin C TangDirectorBuy220,000$22.23$4,890,600.00View SEC Filing  
6/23/2015Kevin C TangDirectorBuy53,836$22.27$1,198,927.72View SEC Filing  
6/22/2015Kevin C TangDirectorBuy77,850$21.41$1,666,768.50View SEC Filing  
5/13/2015Kevin C TangDirectorBuy190,583$18.24$3,476,233.92View SEC Filing  
5/12/2015George F TidmarshCEOBuy4,000$18.37$73,480.00View SEC Filing  
12/15/2014Kevin C TangDirectorBuy232,343$12.84$2,983,284.12View SEC Filing  
12/11/2014George F TidmarshCEOBuy4,000$11.38$45,520.00View SEC Filing  
9/26/2014George F TidmarshCEOBuy2,000$9.35$18,700.00View SEC Filing  
9/26/2014Kevin C TangDirectorBuy169,555$9.14$1,549,732.70View SEC Filing  
9/25/2014Kevin C TangDirectorBuy30,500$9.17$279,685.00View SEC Filing  
9/24/2014Kevin C TangDirectorBuy95,000$9.10$864,500.00View SEC Filing  
9/18/2014George F TidmarshCEOBuy5,000$9.18$45,900.00View SEC Filing  
7/23/2014George F TidmarshCEOBuy19,000$10.50$199,500.00View SEC Filing  
5/21/2014George TidmarshCEOBuy12,000$7.37$88,440.00View SEC Filing  
4/14/2014George TidmarshCEOBuy8,000$9.53$76,240.00View SEC Filing  
2/7/2014George F TidmarshCEOBuy3,000$7.25$21,750.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for La Jolla Pharmaceutical Company (NASDAQ:LJPC)
Latest Headlines for La Jolla Pharmaceutical Company (NASDAQ:LJPC)
Source:
Loading headlines, please wait.

Social

Chart

La Jolla Pharmaceutical Company (LJPC) Chart for Monday, October, 23, 2017

This page was last updated on 10/23/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.